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Abstract 
In chronic lymphocytic leukemia (CLL), NOTCH1 mutations have been associated with clinical 
resistance to the anti-CD20 rituximab, although the mechanisms behind this peculiar behavior 
remain to be clarified. In a wide CLL series (n=692), we demonstrated that CLL cells from 
NOTCH1 mutated cases (87/692) were characterized by lower CD20 expression, and lower relative 
lysis induced by anti-CD20 exposure in-vitro. Consistently, CD20 expression by CLL cells was up-
regulated in-vitro by -secretase inhibitors or NOTCH1-specific siRNA, and the stable transfection 
of a mutated (c.7541-7542delCT) NOTCH1 intracellular domain (NICD-mut) into CLL-like cells 
resulted in a strong downregulation of both CD20 protein and transcript. By using these NICD-mut 
transfectants, we investigated protein interactions of RBPJ, a transcription factor acting either as 
activator or repressor of NOTCH1 pathway when respectively bound to NICD or hystone 
deacetylases (HDACs). Compared to controls, NICD-mut transfectants had RBPJ preferentially 
complexed to NICD, and showed higher levels of HDACs interacting with the promoter of the 
CD20 gene. Finally, treatment with the HDAC inhibitor valproic acid upregulated CD20 in both 
NICD-mut transfectants and primary CLL cells. In conclusion, NOTCH1 mutations are associated 
with low CD20 levels in CLL and are responsible for a dysregulation of HDAC-mediated 
epigenetic repression of CD20 expression. 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Introduction 
 
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with highly variable clinical 
courses and survivals ranging from months to decades. In particular, a subset of CLL patients is 
known to experience a progressive symptomatic disease poorly responsive to the common immuno-
chemotherapeutic regimens.
1,2
 A fraction of these high risk CLL, overall accounting for 5-10% of 
cases, can be identified by screening for TP53 mutation/deletion,
1,2
 while an additional fraction of 
cases has been recently shown to bear mutations involving the NOTCH1, SF3B1 and BIRC3 genes. 
Overall, alterations of these genes occur in approximately 20% of CLL patients at diagnosis and 
have significant correlations with survival in consecutive series from independent institutions.
3-7
 
 
Mutations of NOTCH1 are found in about 10% of CLL cases at diagnosis, with frequency 
increasing in advanced disease phases, in chemorefractory patients, and during transformation to 
Richter Syndrome.
3-5,7,8
 Moreover, NOTCH1 mutations are enriched in CLL patient subgroups 
defined by trisomy 12 and an unmutated IGHV gene status.
9,10
 NOTCH1 encodes for a 
transmembrane receptor acting as a ligand-activated transcription factor.
11,12
 In particular, NOTCH1 
signaling initiates when the ligand, from either the JAGGED or DELTA families, binds to the 
receptor and induces successive proteolytic cleavages, resulting in the release and nuclear 
translocation of the NOTCH1 intra-cellular domain (NICD). In the nucleus, the NICD becomes part 
of an activation complex along with the transcription factor RBPJ, that leads to the de-
repression/activation of specific target genes, including genes of the HES family.
13-20
 At variance 
with normal B cells, CLL cells constitutively express the NOTCH1 receptor as well as its ligands 
JAGGED1 and JAGGED2, suggesting autocrine/paracrine loops for NOTCH1 signaling 
activation.
21
 In CLL, virtually all NOTCH1 mutations are frameshift or non-sense events clustering 
within exon 34, including a highly recurrent c.7541-7542delCT frameshift deletion, represented in 
80% of cases.
3,4,10
 These mutations result in the truncation of the C-PEST regulatory domain of the 
protein and the subsequent impaired degradation of the NICD,
3,4,22-24
 which in turn determines to an 
intense and sustained activation of the NOTCH1 pathway.
25
 
 
Recently, the presence of NOTCH1 mutations has been associated with a relative resistance to anti-
CD20 immunotherapy in a prospective clinical study comparing the effectiveness of the fludarabine 
plus cyclophosphamide (FC) regimen versus the FC plus rituximab (FCR) regimen
26
, although the 
biological mechanisms underlying the differential activity of rituximab in relation to NOTCH1 
mutational status is still to be elucidated. 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Materials and Methods 
 
Primary cells from CLL patients and healthy donors 
The study was approved by the Internal Review Board of the Aviano Centro di Riferimento 
Oncologico (Approval n. IRB-05-2010), and included peripheral blood samples from 692 patients 
with CLL.
27
 Informed consent was obtained in accordance with the declaration of Helsinki. CLL 
cases were characterized for IGHV mutational status, the main cytogenetic abnormalities, CD38, 
CD49d, ZAP70 expression, as described.
28
 
 
Primary CLL cells and normal B cells from healthy donors (n=3) were obtained from peripheral 
blood samples by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient centrifugation 
and used either directly or cryopreserved until use. All studies were performed on highly purified 
cells (>95% pure), as results of negative selection by immunomagnetic beads when required.
29
 In-
vitro studies were performed in CLL cells from NOTCH1 mutated cases with relevant NOTCH1 
mutational burden, i.e >25% of total DNA, or in NOTCH1 wild type cases, as control. 
 
CD20 expression 
CD20 expression was evaluated by flow cytometry at the Clinical and Experimental Onco-
Hematology Unit (CRO, Aviano), in the 692 CLL cases entering this study, as part of the routine 
diagnostic procedures for CLL assessment. In particular, 495 cases were evaluated by a FITC-
conjugated anti-CD20 antibody, while, in the remaining 197 cases, a PE-Cy7-conjugated antibody 
was employed (clone L27, in both cases, BD Biosciences, Milan, Italy), due to a modification of the 
flow cytometry diagnostic panel. For CD20 expression analyses, these two cohorts were kept 
separated. All experiments were performed on FACSCanto II (BD Biosciences, Milan, Italy).
28,29
 
 
NOTCH1 mutational status 
The presence of c.7541-7542delCT NOTCH1 mutation was investigated by amplification refractory 
mutation system (ARMS) PCR, as described.
3,8,10
 The load of c.7541-7542delCT NOTCH1 
mutation was evaluated by next generation sequencing (NGS) using a MiSeq sequencer (Illumina, 
San Diego, CA), with a ~1000X coverage-fold. 
 
The presence of NOTCH1 mutations other than the c.7541-7542delCT was investigated by Sanger 
sequencing in the entire NOTCH1 PEST domain, as reported.
30
 The mutational load was roughly 
determined (about 50%, 25-50%, about 25%, <25% of mutated DNA) by visual inspection of 
sequence electropherograms, as reported.
31
 
 
Cell Sorting 
CLL cells from selected NOTCH1 mutated cases were sorted according to CD20 expression by 
using the PE-conjugated anti-CD20 antibody (BD Biosciences). The CD20
low
 or CD20
high
 fractions 
were selected below the 25
th
 percentile or above the 75
th
 percentile of CD20 expression, 
respectively. After CDC assay, CLL cells from selected NOTCH1 mutated cases were sorted 
according to 7-aminoactinomycin (7-AAD, BD Biosciences) expression. Viable cell fraction was 
identified as 7-AAD-negative. Sorting was performed utilizing a FACSAriaIII cell sorter (BD 
Biosciences), as described.
29
 
 
NICD plasmids and transfection 
NICD Plasmids were engineered cloning the NICD coding sequence in a pcDNA3.1-NT-GFP-
TOPO vector (Life Technologies, Monza, Italy). The c.7541-7542delCT mutation (NICD-mut) or 
c.5304G>A (NICD-null) mutation were inserted with the Quikchange II XL Mutagenesis kit 
©    2015 Macmillan Publishers Limited. All rights reserved.
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(Agilent, Milan, Italy). MEC-1 cells were transfected with the Amaxa Nucleofector (Lonza, Basel, 
Switzerland). 
 
Primary CLL cells were transfected with siRNA for NOTCH1 (TriFECTa, RNAi kit, IDT, Leuven, 
Belgium) using the Amaxa Nucleofector, as reported.
32
 NOTCH1 protein expression was evaluated 
by flow cytometry using the PE-conjugated anti-NOTCH1 antibody (clone MHN1-519, BD 
Biosciences). 
 
Co-immunoprecipitation experiments 
Nuclear extracts were obtained as reported.
33
 Co-immunoprecipitation was performed using anti-
RBPJ (clone ab25949, Abcam) and isotype (Millipore, Milan, Italy) antibodies. WB was performed 
using anti-NOTCH1 (D1E11, CST), anti-HDAC1 (10E2, Abcam), anti-HDAC2 (HDAC2-62, 
Abcam), anti-RBPJ (D10A4, CST) antibodies. Anti-ERK 1/2 (BD Biosciences) and anti-BRG1 
(Santa Cruz Biotechnology, Heidelberg, Germany) were used as loading controls for cytoplasmic 
and nuclear lysates. 
 
Chromatin immunoprecipitation (ChIP) assay 
ChIP assays were performed with SimpleChIP enzymatic Chromatin IP kit (CST), according to 
standard manufacturer’s protocol, using anti-HDAC1 (10E2, Abcam), anti-HDAC2 (HDAC2-62, 
Abcam), anti-Hystone H3 (kit provided) or control isotype (kit provided) antibodies. Qualitative 
PCR amplification of MS4A1 promoter was performed as reported.
34
 Quantification of MS4A1 
promoter DNA was determined by QRT-PCR. 
 
 
Further details regarding the methods and the statistical approaches are provided as Supplementary 
Information. 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Results 
 
NOTCH1 mutational status and NOTCH1 protein expression in CLL 
The presence of the c.7541-7542delCT NOTCH1 mutation was investigated by ARMS PCR in 692 
CLL cases. With this approach, the c.7541-7542delCT was detected in 81 cases (Table S1). 
Additional 6 cases with a NOTCH1 mutation other than the c.7541-7542delCT were detected by 
Sanger sequencing (Table S1). Overall considered, NOTCH1 mutated (NOTCH1-mut) cases 
represented about the 12% (i.e. 87/692 cases) of the cohort, in keeping with previous studies.
3-5
 A 
quantitative detection of the c.7541-7542delCT was performed by NGS. As shown in Table S2, the 
NOTCH1 mutational load ranged from 1% to 50% of total DNA, in agreement with the 
heterozygous nature of NOTCH1 mutations and with its subclonal representation in some 
instances.
3-5
 
 
NOTCH1 protein expression was evaluated by WB in NOTCH1-mut cases, chosen among those 
with high mutational load (i.e. > 25% of NOTCH1 mutated DNA) and, for comparison, in NOTCH1 
wild type (NOTCH1-wt) CLL. In keeping with the presence of the c.7541-7542delCT that generates 
truncated protein with impaired degradation,
35
 NOTCH1-mut cases showed high transmembrane 
NOTCH1 and NICD levels, both with molecular weights consistent with the truncation of the 
NOTCH1 mutated protein (Figure S1).
4,21,25
 Conversely, NOTCH1-wt CLL, although expressing 
discrete amount of transmembrane NOTCH1 in some instances, usually expressed less NICD 
protein than NOTCH1-mut cases (Figure S1).
4,21,25
 
 
Correlation between CD20 expression and NOTCH1 mutational status in CLL 
CD20 expression was investigated by flow cytometry using either a FITC- or a PE-Cy7-conjugated 
antibody (Table S1), and separately analyzed (Figures S2a and S3a). In the cohort of 495 cases (60 
NOTCH1-mut) in which CD20 expression was evaluated by the FITC-conjugated antibody, CD20 
levels were generally lower in the CLL component than in the normal non-neoplastic residual B cell 
counterpart (Figure S2a), as reported.
27
 Moreover, when CLL cases were stratified according to the 
classification of the main cytogenetic aberrations,
36
 variable CD20 levels were found, the highest 
levels being detected in trisomy 12 CLL (Figure S2a).
37
 When the CD20 expression was evaluated 
with respect to NOTCH1 mutational status, NOTCH1-mut CLL expressed lower MFI values than 
NOTCH1-wt cases in both trisomy 12 CLL (mean MFI in 20 NOTCH1-mut cases = 1 893±196; 
mean MFI in 69 NOTCH1-wt cases = 7 051±819; p<0.0001) and non-trisomy 12 CLL (mean MFI 
in 40 NOTCH1-mut cases = 1 858±203; mean MFI in 366 NOTCH1-wt cases = 2 426±112; 
p=0.017, Figures 1a and S2b). 
 
Superimposable results were obtained in the remaining 197 CLL (27 NOTCH1-mut and 170 
NOTCH1-wt cases), in which the CD20 expression was evaluated with a PE-Cy7-conjugated 
antibody (Table S1), both in trisomy 12 CLL (mean MFI in 6 NOTCH1-mut cases = 12 926±3 676; 
mean MFI in 17 NOTCH1-wt cases = 28 216±5 228; p=0.027) and non-trisomy 12 CLL (mean MFI 
in 21 NOTCH1-mut cases = 10 207±1 310; mean MFI in 153 NOTCH1-wt cases = 15 208±1 578; 
p=0.017, Figure S3a,b). 
 
In keeping with flow cytometry results, transcript levels of MS4A1, the gene encoding for CD20,
38
 
as evaluated in 275 cases (46 NOTCH1-mut), were lower in NOTCH1-mut than in NOTCH1-wt 
cases both in the trisomy 12 (p=0.006) and in the non-trisomy 12 (p=0.019) CLL categories (Figure 
1b). 
 
©    2015 Macmillan Publishers Limited. All rights reserved.
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To corroborate the correlation between CD20 expression and NOTCH1 mutations, we performed 
cell sorting experiments to isolate the extreme CD20
low 
and CD20
high
 subpopulations in five CLL 
cases with different NOTCH1 mutational load (Figure S4a), as determined by NGS, i.e. 3% 
(CLL#406), 8% (CLL#34), 27% (CLL#171), 35% (CLL#243) and 41% (CLL#266) of total DNA. 
As shown by NGS re-sequencing of the separated subpopulations, CD20
low 
sorted cells always had 
a relative enrichment in the NOTCH1 mutational burden when compared to the CD20
high
 
counterpart, i.e. 9% vs. 1% (CLL#406), 14% vs. 3% (CLL#34), 32% vs. 15% (CLL#171), 38% vs. 
32% (CLL#243), 48% vs. 39% (CLL#266). Consistently, the amount of MS4A1 transcripts was 
always significantly lower in the CD20
low
 than in the CD20
high
 subpopulation (Figure S4b). 
 
NOTCH1 mutational status and susceptibility to anti-CD20 in CLL 
Then we investigated if NOTCH1 mutational status could effectively influence susceptibility to 
anti-CD20 immunotherapy. To evaluate the capability of rituximab to kill in-vitro CLL cells 
bearing or not NOTCH1 mutations, CDC assay was performed utilizing purified CLL cells from 9 
NOTCH1-mut and 9 NOTCH1-wt cases. NOTCH1-mut CLL cells showed significantly lower 
relative lysis induced by rituximab than NOTCH1-wt CLL cells (mean % of relative lysis = 2.5±0.8 
vs. 26.3±8.9, p=0.021), and the killing capacity of rituximab directly correlated with CD20 levels 
(Figure 1c). 
 
We further investigated the correlation between NOTCH1 mutational status and susceptibility to 
rituximab by evaluating in three NOTCH1-mut cases the enrichment of NOTCH1 mutational burden 
after CDC assay upon rituximab and subsequent cell sorting of the residual viable cell population. 
The NOTCH1 mutational burden, as detected by NGS, resulted higher in the post-CDC sorted 
viable cells than in the pre-CDC unsorted counterpart in all the three tested cases (Figure S4c). 
Consistently, the amount of MS4A1 transcripts, as detected by QRT-PCR, were lower in the viable 
cell populations than in the pre-CDC unsorted counterparts (Figure S4c). 
 
We also evaluated the capability of the alternative anti-CD20 antibody ofatumumab to kill in-vitro 
CLL cells from 9 NOTCH1-mut and 9 NOTCH1-wt cases. Although the killing capacity of 
ofatumumab resulted generally higher than that of rituximab, NOTCH1-mut CLL cells showed 
significantly lower relative lysis than NOTCH1-wt CLL cells (mean % of relative lysis = 30.6±8.5 
vs. 60.6±5.8, p=0.011), again consistently with CD20 expression levels (Figure 1d). 
 
NOTCH1 signaling and CD20 expression in CLL 
To evaluate if NOTCH1 signaling could influence CD20 expression in primary CLL cases, CLL 
cells from 5 NOTCH1-mut and 6 NOTCH1-wt cases were treated at different time points with the 
GSI L-685,458, able to block the proteolytic generation of NICD.
21
 Upon GSI treatment, NOTCH1 
signaling was consistently impaired, as defined by a reduction of HES1 expression (at 6 hours) in 
both NOTCH1-wt and NOTCH1-mut CLL, although decreases were lower in the NOTCH1-mut 
category (p=0.005), according to the presence of higher levels of NICD in the latter cases (Figure 
S5a and Figure S1). More important, both MS4A1 transcripts (at 6 hours) and CD20 expression 
levels (at 24 hours) were significantly upregulated by GSI in NOTCH1-wt and, to a lesser extent, in 
NOTCH1-mut cases (Figure S5b). No effect on CD20 expression was observed in purified normal 
B cells from healthy donors exposed in-vitro to GSI, in keeping with the notion of a lack of 
NOTCH1 expression in these cells (not shown).
21
 
 
To further confirm the association between NOTCH1 signaling and CD20 expression, CLL cells 
from 6 NOTCH1-mut and 5 NOTCH1-wt cases were transiently transfected with siRNA for 
NOTCH1. In both NOTCH1-mut and NOTCH1-wt cases, siRNA transfection effectively reduced 
©    2015 Macmillan Publishers Limited. All rights reserved.
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NOTCH1 transcript at 6 hours (p=0.001, not shown) and protein at 24 hours (NOTCH1-mut cases, 
mean MFI = 538±119 vs. 184±32, p=0.011; NOTCH1-wt cases, mean MFI = 524±64 vs. 204±17, 
p=0.003). Consistently, CD20 expression resulted augmented both at transcript level (at 6 hours, 
NOTCH1-mut, p=0.034, NOTCH1-wt, p= 0.012, not shown) and protein level (at 24 hours, 
NOTCH1-mut cases, mean MFI = 2685±887 vs. 3035±916, p=0.001; NOTCH1-wt cases, mean MFI 
= 1707±434 vs. 1923±434, p=0.003, Figure S5c). 
 
Establishment of an in-vitro model of mutated NICD-transfected CLL-like cells 
To investigate the mechanism(s) through which NOTCH1 mutations may affect CD20 expression in 
CLL, we established an in-vitro model of NICD transfected cells by taking advantage of the CLL-
like MEC-1 cell line. MEC-1 cells, constitutively expressing a wild-type NOTCH1 form, were 
stably transfected with vectors encoding for: i) a modified NICD with the c.7541-7542delCT 
(NICD-mut); ii) a modified NICD with a nonsense mutation inserted after the beginning of the 
coding sequence, as a null control (NICD-null). NICD-mut cells showed higher constitutive 
NOTCH1 protein levels than NICD-null cells (Figure 2a). Consistently, HES1 and HES5 transcript 
levels were higher in NICD-mut than in NICD-null cells (Figure S6a). 
 
When CD20 expression was tested, NICD-mut cells showed constitutive lower CD20 expression at 
both protein and transcript level than NICD-null cells (Figures 2a,b and S6b), and, consistently, 
lower relative lysis induced by rituximab and ofatumumab by CDC assay (p=0.043, p=0.025, 
respectively, Figure 2c). Moreover, upon GSI treatment, CD20 protein and transcript expression 
was significantly up-regulated in both NICD-null cells and NICD-mut cells (Figure 2d and not 
shown). 
 
According to these validations, we assumed the NICD-mut cells as in-vitro model of NOTCH1-mut 
CLL, in which the increased NICD accumulation, due to a decreased degradation of truncated 
form,
15
 is mimicked by the enforced expression of an exogenously transfected mutated NICD. 
 
Immunoprecipitation of the RBPJ transcription factor in NICD transfectants 
When released by proteolytic cleavages and translocated into the nucleus upon activation of the 
NOTCH1 pathway, NICD interacts with the RBPJ transcription factor and converts its function 
from repressor to activator of gene transcription.
13,15,35
 In fact, NICD is able to displace RBPJ from 
a HDAC-containing repression complex, thus forming, with RBPJ itself and other co-activators, the 
major gene transcriptional activation complex of the NOTCH1 pathway.
13,15,35
 
 
To evaluate whether NICD accumulation, as it occurs upon NOTCH1 mutations, could alter the 
balancing of the two functions of RBPJ, i.e. transcriptional activator (complexed with NICD) or 
transcriptional repressor (complexed with HDACs),
13,15
 we performed co-immunoprecipitation 
experiments aimed at investigating the alternative presence of NICD or HDACs (namely HDAC1 
and HDAC2) bound to RBPJ in NICD transfectants. As shown in Figure 3a, co-
immunoprecipitation experiments revealed that NICD-mut cells had higher levels of NICD bound 
with RBPJ than NICD-null cells. On the contrary, NICD-mut cells showed lower levels of HDAC1 
or HDAC2 co-immunoprecipitated with RBPJ than NICD-null cells (Figure 3a). Notably, no 
difference was found by comparing NICD transfectants regarding the levels of immunoprecipitated 
RBPJ, and the nuclear and cytoplasmic levels of RBPJ, HDAC1 and HDAC2, as evidenced by 
control WB experiments (Figure S7a,b,c). Consistently, comparable constitutive HDAC1/HDAC2 
expression levels were found in NOTCH1-mut versus NOTCH1-wt primary CLL (Figure S8). 
 
©    2015 Macmillan Publishers Limited. All rights reserved.
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The un-balancing of the transcriptional activation/repression equilibrium of RBPJ turned in favor of 
the activation of NOTCH1 signaling detected in NICD-mut cells was also in keeping with the 
higher HES1 and HES5 transcript levels detected in these cells (Figure S6a). 
 
HDAC-mediated ChIP in NICD transfectants 
Previous studies identified epigenetic silencing of CD20 expression via HDACs as a mechanism 
conferring resistance to rituximab in lymphomas.
34,39,40
 To evaluate whether the preferential 
interaction of RBPJ with NICD could result in higher levels of HDAC1/HDAC2 available for the 
transcriptional repression of MS4A1,
13,15
 ChIP assays were performed on nuclear lysates from 
NICD transfectants. As shown in Figure 3b, higher levels of DNA corresponding to the MS4A1 
promoter were found in HDAC1 and HDAC2 chromatin immunoprecipitates from NICD-mut 
compared to NICD-null cells. Of note, a higher involvement of HDAC2 with respect to HDAC1 
was evidenced ChIP experiments, in keeping with the higher levels of HDAC2 expressed by NICD 
transfectants (Figure S7c). On the other hand, lower levels of DNA corresponding to the HES1 
promoter were found by ChIP of NICD-mut cells compared to NICD-null cells (not shown). 
 
These results suggest that higher NICD levels, as occurring in NICD-mut cells, may cause a NICD-
dependent dislodgement of RBPJ from the HDAC-containing repression complexes. This 
phenomenon is associated with an increased availability of HDACs to repress transcription of the 
MS4A1 gene. 
 
HDAC inhibition and CD20 expression 
To further evaluate if the higher levels of HDACs bound to the MS4A1 promoter could effectively 
affect CD20 expression, NICD transfected cells were treated with the HDAC inhibitor VPA for 48 
hours. In both NICD-mut and NICD-null cells, VPA treatment was able to significantly increase 
MS4A1 transcript levels (NICD-mut, mean fold increase =1.7, p=0.001; NICD-null, mean fold 
increase =1.5 p=0.003, Figure S9a) and CD20 protein expression (NICD-mut, mean fold increase 
=1.3, p=0.041; NICD-null, mean fold increase =1.4, p=0.029, Figures 4a and S9b). 
 
Similar results were obtained by treating with VPA primary CLL cells of 7 NOTCH1-mut and 6 
NOTCH1-wt cases. In both categories, VPA treatment was able to significantly increase MS4A1 
transcripts (NOTCH1-mut, mean fold increase =1.5, p=0.05; NOTCH1-wt, mean fold increase = 
1.8, p=0.02, Figure S9c) and CD20 protein (NOTCH1-mut, mean fold increase = 1.3, p=0.05; 
NOTCH1-wt, mean fold increase = 1.3, p=0.005, Figures 4b and S9d). These increments were not 
associated with significant increases of relative lysis by in-vitro CDC assays (not shown). 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Discussion 
 
The FCR immuno-chemotherapy combination still represents the frontline regimen for treatment of 
patients in good physical conditions.
1,2
 In particular, the addition of rituximab to the FC 
combination has been definitely proved to improve the clinical outcome of CLL patients, despite 
the relative low levels of CD20 usually expressed on the surface of CLL cells.
26,27
 Recently, 
however, it has been clearly demonstrated that such a benefit does not include patients affected by 
CLL bearing NOTCH1 mutations,
26,41
 although the reason for this different clinical behaviour 
remains to be elucidated. 
 
In the present study, we demonstrated that NOTCH1 mutations identify a CLL subset characterized 
by particularly low levels of CD20, both in non-trisomy 12 CLL, and in the trisomy 12 CLL 
category, that usually has relatively higher CD20 levels and a higher frequency of NOTCH1 
mutations.
9,10,37
 Conversely, Stilgenbauer et al did not find any difference in CD20 expression 
between NOTCH1-mut and NOTCH1-wt CLL although in this study CD20 levels were checked 
exclusively by flow cytometry in a minority of cases.
26
 Here, the lower CD20 expression by 
NOTCH1-mut cases was corroborated by the parallel finding of lower MS4A1 transcript levels. 
Moreover, in cell sorting experiments of CLL cases with different NOTCH1 mutation levels, higher 
percentages of NOTCH1 mutated DNA were found in the sorted CD20
low
 component compared to 
the CD20
high
 counterpart. Finally, the dramatic downregulation of CD20 expression levels obtained 
by stably transfecting the CLL-like MEC-1 cells with a mutated NICD definitely confirmed this 
inverse correlation. 
 
The low CD20 expression by NOTCH1-mut CLL cells is consistent with their lower sensitivity to 
rituximab and ofatumumab exposure in-vitro, as shown here, in agreement with previous reports.
42
 
Results of the present study also indicate that the residual CLL cells surviving upon CDC assay 
with rituximab, usually expressed lower CD20 levels and a greater NOTCH1 mutational load. In 
keeping, NOTCH1 mutations have been demonstrated to impact on rituximab sensitivity of CLL 
patients also when present at subclonal level.
26,41,43
 
 
These data may also suggest that, in CLL, the constitutive expression of NOTCH1, in its mutated 
configuration but also in the wild type form,
21
 could be related with the generally lower CD20 
levels observed in neoplastic versus normal B cells, in which NOTCH1 is not expressed at all.
21
 In 
keeping, we demonstrated here that GSI treatment in-vitro was able to substantially augment CD20 
expression both in NOTCH1-wt and NOTCH1-mut CLL cells, although in the latter the 
accumulation of NICD due to truncating mutations makes these cells relatively less susceptible to 
NOTCH1 signaling perturbation. Since theoretically GSI may have off-target genes,
44
 NOTCH1 
was also inhibited by specific siRNA. Again, transfection with siRNA increased CD20 expression 
both in NOTCH1-wt and NOTCH1-mut CLL cells.
35
 
 
In humans, the balance of hystone acetylation/deacetylation, respectively induced by hystone acetyl 
transferases and HDACs, represents one of the main epigenetic mechanisms of modification of 
chromatin conformation and regulation of gene expression.
45,46
 In particular, the transcriptional 
activity due to the triggering of the NOTCH1 pathway is known to be greatly sensitive to chromatin 
modifications and hystone rearrangements.
35
 In this context, the main effector of the NOTCH1 
pathway at nuclear level is a DNA-binding protein named RBPJ.
13,15,35
 This protein, in association 
with NICD and other co-activators forms an activation complex that is essential for NICD-
dependent transcription and target gene expression. Such an activation complex is degraded via 
NICD phosphorylation, and its subsequent ubiquitination, these molecular reactions requiring an 
©    2015 Macmillan Publishers Limited. All rights reserved.
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intact C-terminal PEST region of the NICD protein.
13,15,35
 The specific degradation of NICD results 
in the dissociation among RBPJ and the other co-activators. In the absence of NICD, RBPJ is free 
to associate with specific co-repressors, which in turn recruit HDAC1 and HDAC2; this newly 
obtained repression complex represses NOTCH1 signaling.
13,15,35
. A simplified scheme of these 
multi-protein interactions is reported in Figure 5a. 
 
Results of this study suggest that NOTCH1 with C-terminal truncations, as those determined by the 
c.7541-7542delCT, may influence the epigenetic downregulation of CD20 by HDACs allegedly via 
an impaired ubiquitination and degradation of the truncated NICD. In fact, as defined by co-
immunoprecipitation experiments, in the condition of NICD accumulation due to the c.7541-
7542delCT, RBPJ showed a preferential binding to NICD, in the context of the activation complex, 
rather than to HDACs, in the context of the repression complex. In NICD-mut cells, in turn, 
HDACs were mainly associated to the MS4A1 promoter, as defined by ChIP experiments. A 
necessary prerequisite is the persistence of the activation complex due to the lack of degradation of 
the truncated NICD (Figure 5b).
13,15,35
 In keeping, the rare NOTCH1-mut CLL carrying truncating 
mutations other than the c.7541-7542delCT (6 cases in our cohort) were all characterized by low 
CD20 levels, comparable with those of NOTCH1-mut CLL carrying the c.7541-7542delCT. 
Conversely, three cases (not included in this cohort) carrying NOTCH1 missense mutations (e.g. 
p.G2292R, p.V2214M and p.T2484M) expressed CD20 levels comparable with those of NOTCH1-
wt CLL (F.P., personal communication). 
 
To restore epigenetic regulation, a wide range of compounds inhibiting HDAC functionality have 
been identified, some of them employed in anticancer therapies.
45,46
 In addition, HDAC inhibitors 
are known to augment the cytotoxic activity of rituximab by increasing CD20 expression in 
lymphoma cells.
34,39,40
 In this study, treatment with the HDAC inhibitor VPA was capable to up-
regulate both MS4A1 transcript and CD20 protein either in NICD transfected cells or in primary 
CLL cells from NOTCH1-mut and NOTCH1-wt cases. 
 
In conclusion, we provided evidence that truncating NOTCH1 mutations in CLL are associated with 
low CD20 expression, and with a relative resistance to anti-CD20 immunotherapy in-vitro. The low 
CD20 expression in NOTCH1- mut CLL can be ascribed to a NOTCH1 mutation-driven epigenetic 
dysregulation of a transcriptional repression mechanism involving HDACs. Clinically, drugs 
interfering with the NOTCH1 pathway and/or inhibiting HDACs might have a role to increase 
CD20 expression in-vivo, thus overcoming the relative resistance of NOTCH1-mut CLL to 
rituximab-containing therapies. 
©    2015 Macmillan Publishers Limited. All rights reserved.
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Figure legends 
 
Figure 1. Correlation between NOTCH1 mutations, CD20 expression, and susceptibility to 
anti-CD20 antibodies in CLL (a) Box-and-whiskers plots showing CD20 protein expression 
levels, evaluated as above, in 89 trisomy 12 CLL cases (20 NOTCH1-mut cases, 69 NOTCH1-wt 
cases) and 406 non-trisomy 12 CLL cases (40 NOTCH1-mut cases, 366 NOTCH1-wt cases). The 
corresponding p values are reported. (b) Box-and-whiskers plots showing MS4A1 transcript 
expression levels, as evaluated by QRT-PCR, in 52 trisomy 12 CLL cases (15 NOTCH1-mut cases, 
37 NOTCH1-wt cases) and 223 non-trisomy 12 CLL cases (31 NOTCH1-mut cases, 192 NOTCH1-
wt cases). The corresponding p values are reported. (c) Box-and-whiskers plots showing the 
percentage of relative lysis of CLL cells, from NOTCH1-mut and NOTCH1-wt CLL cases, treated 
with rituximab in a standard CDC assay. The corresponding p value is reported (left panel). 
Correlation graph showing CD20 expression versus percentage of relative lysis in NOTCH1-mut 
and NOTCH1-wt CLL cases, as evaluated by CDC assay (r= Pearson correlation coefficient, right 
panel). (d) Box-and-whiskers plots showing the percentage of relative lysis of CLL cells, from 
NOTCH1-mut and NOTCH1-wt CLL cases, treated with ofatumumab in a standard CDC assay. The 
corresponding p value is reported (left panel). Correlation graph showing CD20 expression versus 
percentage of relative lysis in NOTCH1-mut and NOTCH1-wt CLL cases, as evaluated by CDC 
assay (r= Pearson correlation coefficient, right panel). 
 
Figure 2. Establishment of an in-vitro model of mutated NICD-transfected CLL-like cells. (a) 
NOTCH1 and CD20 protein expression levels of NICD-null and NICD-mut cells, as evaluated by 
WB. β-actin was used as loading control. Exogenous transfected mutated NICD is indicated as 
GFP-NICD, endogenous NICD is indicated as NICD. (b) Histograms (left panel) and box-and-
whiskers plots (right panel) showing constitutive MS4A1 transcript and CD20 protein expression 
levels of NICD-null and NICD-mut cells, as evaluated by QRT-PCR and flow cytometry, 
respectively. The corresponding p values are reported. (c) Box-and-whiskers plots showing the 
percentage of relative lysis of NICD-null (empty histogram) and NICD-mut cells (grey histogram), 
upon rituximab or ofatumumab, as evaluated by CDC assay. The corresponding p value are 
reported. Results of three independent experiments are reported. (d) Box-and-whiskers plots 
showing CD20 protein expression levels of NICD-null and NICD-mut cells, untreated (UNT) and 
upon GSI treatment (GSI) for 24 hours, as evaluated by flow cytometry. The corresponding p 
values are reported. Results of three independent experiments are reported. 
 
Figure 3. Characterization of a HDAC dependent epigenetic repression mechanism of CD20 
expression in NICD transfected cells. (a) Immunoblotting with antibodies recognizing the total 
NOTCH1 (upper panel), HDAC1 (middle panel), and HDAC2 (lower panel) in whole nuclear 
lysates (WNL), immunoprecipitates with isotypic control (ISO) and immunoprecipitated with RBPJ 
(RBPJ) derived from NICD-mut and NICD-null cells. Exogenous transfected mutated NICD is 
indicated as GFP-NICD, endogenous NICD is indicated as NICD. (b) Analysis of the MS4A1 
promoter in total chromatin preparation (INPUT), and ChIP with isotypic control (ISO), antibodies 
recognizing HDAC1 and HDAC2, as evaluated by qualitative PCR (upper panel). Results from a 
representative experiment out of three experiments is reported. Analysis of the MS4A1 promoter in 
ChIP with isotypic control (ISO), antibodies recognizing HDAC1 and HDAC2, as evaluated by 
QRT-PCR (lower panel). Results of three independent experiments are reported. 
 
Figure 4. Induction of CD20 expression by HDAC inhibition in NICD transfectants and in 
primary CLL cells. (a) Box-and-whiskers plots showing CD20 protein expression levels of NICD-
mut and NICD-null cells, untreated (UNT) and VPA treated (VPA) for 48 hours, as evaluated by 
©    2015 Macmillan Publishers Limited. All rights reserved.
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flow cytometry. The corresponding p values are reported. Results of three independent experiments 
are showed. (b) Dot-and-line diagrams showing CD20 expression levels in primary CLL cells, 
untreated (UNT) and VPA treated (VPA) for 48 hours, from NOTCH1-mut and NOTCH1-wt cases, 
as evaluated by flow cytometry. The corresponding p values are reported. 
 
Figure 5. Putative model of a NOTCH1 mutation-dependent mechanism of CD20 down-
regulation via HDAC1/HDAC2 epigenetic repression in CLL. (a) Regulated balancing in 
NOTCH1-wt CLL (phospho, phosphorylation; ub, ubiquitination; Co-A, co-activators; Co-R, co-
repressors). (b) Dysregulated balancing in NOTCH1-mut CLL. See text for further details. 
©    2015 Macmillan Publishers Limited. All rights reserved.
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